TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery
Brief Summary: A randomized, placebo-controlled pilot study to determine endoscopic recurrence of Crohn's disease 12 months after curative, resective ileal or ileocolonic surgery in patients receiving post-operative infliximab or placebo


Options:
A: Arm Label: Systematic azathioprine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine, Procedure: Ileocolonoscopy, Procedure: Small bowel follow trough | Arm Label: Endoscopy-driven azathioprine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine in case of endoscopic recurrence, Procedure: Ileocolonoscopy, Procedure: Small bowel follow trough | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Systematic azathioprine group | Intervention Type: DRUG; Name: Azathioprine in case of endoscopic recurrence; Assigned to Arm(s): Endoscopy-driven azathioprine group | Intervention Type: PROCEDURE; Name: Ileocolonoscopy; Assigned to Arm(s): Endoscopy-driven azathioprine group, Systematic azathioprine group | Intervention Type: PROCEDURE; Name: Small bowel follow trough; Assigned to Arm(s): Endoscopy-driven azathioprine group, Systematic azathioprine group
B: Arm Label: Metronidazole + Azathioprine.; Type: EXPERIMENTAL; Interventions: Drug: Metronidazole, Drug: Azathioprine | Arm Label: Metronidazole + Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metronidazole, Drug: Adalimumab | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole + Azathioprine. | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole + Adalimumab | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Metronidazole + Azathioprine. | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Metronidazole + Adalimumab
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: infliximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: Azathioprine; Type: EXPERIMENTAL; Interventions: Drug: Azathioprine, Drug: Mesalazine placebo | Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine, Drug: Azathioprine placebo | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Azathioprine | Intervention Type: DRUG; Name: Mesalazine; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Azathioprine placebo; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Mesalazine placebo; Assigned to Arm(s): Azathioprine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Controlled Trial Comparing Bispectral Index Monitoring to Electronic Alerts for Prevention of Awareness During Anesthesia in the General Population
Brief Summary: Awareness during anesthesia is a problem receiving increased attention by patients, clinicians, and the general public. The incidence of intraoperative awareness has been reported to be between 1-2/1000 cases, but recent data suggest that this may be an overestimate. The Bispectral Index (BIS) Monitor is an electroencephalographic method of assessing depth of anesthesia that has been shown in one study to reduce the incidence of awareness during anesthesia in the high-risk population (Myles et al, 2004). In the study of Myles et al, the number needed to treat (NNT) in order to prevent one case of awareness in the high-risk population was 138, with an associated cost of approximately US$2200. Since the NNT and the associated cost of treatment would be much higher in the general population, the efficacy of the BIS monitor in preventing awareness in all anesthetized patients needs to be clearly established. Furthermore, recent data suggest that the BIS may not be useful in the high-risk population. The investigators propose a prospective, randomized, controlled trial comparing the BIS monitor to electronic alerts based on non-electroencephalographic gauges of anesthetic depth.


Options:
A: Arm Label: Xenon; Type: EXPERIMENTAL; Interventions: Drug: Xenon | Arm Label: Sevoflurane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevoflurane | Intervention Type: DRUG; Name: Xenon; Assigned to Arm(s): Xenon | Intervention Type: DRUG; Name: Sevoflurane; Assigned to Arm(s): Sevoflurane
B: Arm Label: Deeper sedation; Type: ACTIVE_COMPARATOR; Interventions: Device: Deeper sedation | Arm Label: Moderate sedation; Type: ACTIVE_COMPARATOR; Interventions: Device: Moderate sedation | Intervention Type: DEVICE; Name: Deeper sedation; Assigned to Arm(s): Deeper sedation | Intervention Type: DEVICE; Name: Moderate sedation; Assigned to Arm(s): Moderate sedation
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rivastigmine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivastigmine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: BIS group; Type: EXPERIMENTAL; Interventions: Device: Bispectral Index Monitor | Arm Label: MAC Alert; Type: ACTIVE_COMPARATOR; Interventions: Device: Electronic MAC alert | Intervention Type: DEVICE; Name: Bispectral Index Monitor; Assigned to Arm(s): BIS group | Intervention Type: DEVICE; Name: Electronic MAC alert; Assigned to Arm(s): MAC Alert

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Controlled Trial Comparing Bispectral Index Monitoring to Electronic Alerts for Prevention of Awareness During Anesthesia in the General Population
Brief Summary: Awareness during anesthesia is a problem receiving increased attention by patients, clinicians, and the general public. The incidence of intraoperative awareness has been reported to be between 1-2/1000 cases, but recent data suggest that this may be an overestimate. The Bispectral Index (BIS) Monitor is an electroencephalographic method of assessing depth of anesthesia that has been shown in one study to reduce the incidence of awareness during anesthesia in the high-risk population (Myles et al, 2004). In the study of Myles et al, the number needed to treat (NNT) in order to prevent one case of awareness in the high-risk population was 138, with an associated cost of approximately US$2200. Since the NNT and the associated cost of treatment would be much higher in the general population, the efficacy of the BIS monitor in preventing awareness in all anesthetized patients needs to be clearly established. Furthermore, recent data suggest that the BIS may not be useful in the high-risk population. The investigators propose a prospective, randomized, controlled trial comparing the BIS monitor to electronic alerts based on non-electroencephalographic gauges of anesthetic depth.


Options:
A: Intervention Type: DRUG; Name: Nitrous Oxide; Assigned to Arm(s): N/A
B: Arm Label: BIS Monitor guided algorithm; Type: EXPERIMENTAL; Interventions: Device: BIS Monitor guided algorithm | Arm Label: Volatile anesthetic guided algorithm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Volatile anesthetic guided algorithm | Intervention Type: DEVICE; Name: BIS Monitor guided algorithm; Assigned to Arm(s): BIS Monitor guided algorithm | Intervention Type: BEHAVIORAL; Name: Volatile anesthetic guided algorithm; Assigned to Arm(s): Volatile anesthetic guided algorithm
C: Arm Label: BIS group; Type: EXPERIMENTAL; Interventions: Device: Bispectral Index Monitor | Arm Label: MAC Alert; Type: ACTIVE_COMPARATOR; Interventions: Device: Electronic MAC alert | Intervention Type: DEVICE; Name: Bispectral Index Monitor; Assigned to Arm(s): BIS group | Intervention Type: DEVICE; Name: Electronic MAC alert; Assigned to Arm(s): MAC Alert
D: Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Arm Label: Propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): Propofol | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Midazolam

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Controlled Trial Comparing Bispectral Index Monitoring to Electronic Alerts for Prevention of Awareness During Anesthesia in the General Population
Brief Summary: Awareness during anesthesia is a problem receiving increased attention by patients, clinicians, and the general public. The incidence of intraoperative awareness has been reported to be between 1-2/1000 cases, but recent data suggest that this may be an overestimate. The Bispectral Index (BIS) Monitor is an electroencephalographic method of assessing depth of anesthesia that has been shown in one study to reduce the incidence of awareness during anesthesia in the high-risk population (Myles et al, 2004). In the study of Myles et al, the number needed to treat (NNT) in order to prevent one case of awareness in the high-risk population was 138, with an associated cost of approximately US$2200. Since the NNT and the associated cost of treatment would be much higher in the general population, the efficacy of the BIS monitor in preventing awareness in all anesthetized patients needs to be clearly established. Furthermore, recent data suggest that the BIS may not be useful in the high-risk population. The investigators propose a prospective, randomized, controlled trial comparing the BIS monitor to electronic alerts based on non-electroencephalographic gauges of anesthetic depth.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: air | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nitrous oxide | Intervention Type: DRUG; Name: air; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nitrous oxide; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Nitrous Oxide; Assigned to Arm(s): N/A
C: Arm Label: BIS group; Type: EXPERIMENTAL; Interventions: Device: Bispectral Index Monitor | Arm Label: MAC Alert; Type: ACTIVE_COMPARATOR; Interventions: Device: Electronic MAC alert | Intervention Type: DEVICE; Name: Bispectral Index Monitor; Assigned to Arm(s): BIS group | Intervention Type: DEVICE; Name: Electronic MAC alert; Assigned to Arm(s): MAC Alert
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Bispectral index protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: End tidal anesthetic gas-guided | Intervention Type: BEHAVIORAL; Name: Bispectral index protocol; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: End tidal anesthetic gas-guided; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder
Brief Summary: The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.


Options:
A: Arm Label: Botox A; Type: EXPERIMENTAL; Interventions: Drug: Botulinum toxin A (Botox A®) | Arm Label: Standardized Anticholinergic Regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin 5mg, Drug: Solifenacin 10mg, Drug: Trospium chloride | Intervention Type: DRUG; Name: Botulinum toxin A (Botox A®); Assigned to Arm(s): Botox A | Intervention Type: DRUG; Name: Solifenacin 5mg; Assigned to Arm(s): Standardized Anticholinergic Regimen | Intervention Type: DRUG; Name: Solifenacin 10mg; Assigned to Arm(s): Standardized Anticholinergic Regimen | Intervention Type: DRUG; Name: Trospium chloride; Assigned to Arm(s): Standardized Anticholinergic Regimen
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to Mirabegron, Drug: Placebo to Tolterodine | Arm Label: Mirabegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Placebo to Tolterodine | Arm Label: Mirabegron 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Placebo to Tolterodine | Arm Label: Tolterodine SR 4 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolterodine, Drug: Placebo to Mirabegron | Intervention Type: DRUG; Name: Mirabegron; Assigned to Arm(s): Mirabegron 100 mg, Mirabegron 50 mg | Intervention Type: DRUG; Name: Tolterodine; Assigned to Arm(s): Tolterodine SR 4 mg | Intervention Type: DRUG; Name: Placebo to Mirabegron; Assigned to Arm(s): Placebo, Tolterodine SR 4 mg | Intervention Type: DRUG; Name: Placebo to Tolterodine; Assigned to Arm(s): Mirabegron 100 mg, Mirabegron 50 mg, Placebo
C: Arm Label: Fesoterodine; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fesoterodine; Assigned to Arm(s): Fesoterodine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: TROSPIUM CHLORIDE; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trospium Chloride | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trospium Chloride; Assigned to Arm(s): TROSPIUM CHLORIDE | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLACEBO

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC)
Brief Summary: CENTRIC is a Phase 3 clinical trial assessing efficacy and safety of the investigational integrin inhibitor, cilengitide, in combination with standard treatment versus standard treatment alone in newly diagnosed glioblastoma subjects with a methylated O6-methylguanine-deoxyribonucleic acid methyltransferase (MGMT) gene promoter in the tumor tissue.

The MGMT gene promoter is a section of deoxyribonucleic acid (DNA) that acts as a controlling element in the expression of MGMT. Methylation of the MGMT gene promoter has been found to be a predictive marker for benefit from temozolomide (TMZ) treatment.


Options:
A: Arm Label: Cilengitide + Temozolomide + Radiotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cilengitide, Drug: Temozolomide, Radiation: Radiotherapy | Arm Label: Temozolomide + Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide, Radiation: Radiotherapy | Intervention Type: DRUG; Name: Cilengitide; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy, Temozolomide + Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy, Temozolomide + Radiotherapy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2
C: Arm Label: Cediranib & Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: gefitinib | Arm Label: Cediranbib & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: Placebo | Intervention Type: DRUG; Name: cediranib maleate; Assigned to Arm(s): Cediranbib & placebo, Cediranib & Gefitinib | Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): Cediranib & Gefitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cediranbib & placebo
D: Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Emulsion Formulation U0267 , Versus Vehicle Foam in Subjects With Plaque-type Psoriasis
Brief Summary: The purpose of the study is to demonstrate the safety and efficacy of U0267 in subjects with plaque-type psoriasis.


Options:
A: Arm Label: Group 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: WBI-1001 | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: WBI-1001 | Intervention Type: DRUG; Name: WBI-1001; Assigned to Arm(s): Group 1, Group 2
B: Arm Label: U0267 foam; Type: EXPERIMENTAL; Interventions: Drug: U0267 Foam | Arm Label: Vehicle foam; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle foam | Intervention Type: DRUG; Name: U0267 Foam; Assigned to Arm(s): U0267 foam | Intervention Type: DRUG; Name: Vehicle foam; Assigned to Arm(s): Vehicle foam
C: Arm Label: U0267 Foam; Type: EXPERIMENTAL; Interventions: Drug: U0267 | Arm Label: Vehicle foam; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: U0267; Assigned to Arm(s): U0267 Foam | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle foam
D: Intervention Type: DRUG; Name: Calcipotriol plus betamethasone dipropionate (LEO80185 gel); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial
Brief Summary: Patients who continue to smoke after a heart attack have a 35% increased risk of a recurrent event or death compared with those who quit. Many patients attempt to stop smoking after a heart attack, but relapse rates approach 66%. A variety of smoking cessation aids have been shown to be effective for the general population. However, bupropion is the only non-nicotine replacement therapy shown to improve abstinence rates in healthy young smokers. Furthermore, nicotine replacement therapies (NRTs) are contraindicated in the immediate period following a heart attack because of the undesirable effects of nicotine. Although bupropion has been successfully used to reduce smoking rates in healthy young populations, its efficacy and safety in the setting of patients recovering from an ACS is unknown. These patients, if they continue to smoke, are at exceptionally high risk for recurrent cardiac events. If bupropion is effective in this population, it will have a major impact on secondary prevention of recurrent clinical events in patients who suffer a heart attack.


Options:
A: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: intensive multi-disciplinary education program on tobacco treatment for pharmacists | Arm Label: Control arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Control arm | Intervention Type: BEHAVIORAL; Name: intensive multi-disciplinary education program on tobacco treatment for pharmacists; Assigned to Arm(s): Intervention arm | Intervention Type: OTHER; Name: Control arm; Assigned to Arm(s): Control arm
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch
C: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
D: Arm Label: Participants; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial
Brief Summary: Patients who continue to smoke after a heart attack have a 35% increased risk of a recurrent event or death compared with those who quit. Many patients attempt to stop smoking after a heart attack, but relapse rates approach 66%. A variety of smoking cessation aids have been shown to be effective for the general population. However, bupropion is the only non-nicotine replacement therapy shown to improve abstinence rates in healthy young smokers. Furthermore, nicotine replacement therapies (NRTs) are contraindicated in the immediate period following a heart attack because of the undesirable effects of nicotine. Although bupropion has been successfully used to reduce smoking rates in healthy young populations, its efficacy and safety in the setting of patients recovering from an ACS is unknown. These patients, if they continue to smoke, are at exceptionally high risk for recurrent cardiac events. If bupropion is effective in this population, it will have a major impact on secondary prevention of recurrent clinical events in patients who suffer a heart attack.


Options:
A: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
B: Intervention Type: DRUG; Name: bupropion SR (sustained-release); Assigned to Arm(s): N/A
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate (CP-526, 555-18) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: varenicline tartrate (CP-526, 555-18); Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Varenicline pre-treatmemt; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Placebo, Varenicline pre-treatmemt | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A